Dateline City:
MALVERN, Pa. & KENILWORTH, N.J.
MALVERN, Pa. & KENILWORTH, N.J.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage
biopharmaceutical company focused on discovering and developing novel
small molecule therapeutics in oncology and infectious diseases, and
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today they have entered into an oncology clinical study
collaboration.
Language:
English
Contact:
Merck Media Relations:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orTetraLogic Investor Relations:Pete A. Meyers, 610-889-9900, x103pete.meyers@tlog.com
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more